ANIP - ANIファ―マシュ―ティカルズ (ANI Pharmaceuticals Inc.) ANIファ―マシュ―ティカルズ

 ANIPのチャート


 ANIPの企業情報

symbol ANIP
会社名 ANI Pharmaceuticals Inc (ANIファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ANIファーマシューティカル(ANI Pharmaceuticals Inc.)は統合・専門的製薬会社である。同社はブランド医薬品とジェネリック医薬品の開発、製造、マーケティングに従事する。同社は抗癌剤(抗腫瘍剤)、ホルモンおよびステロイド、複合的製剤を提供する。同社はまた、他の製薬会社の請負製造を行う。製品には、ブランド医薬品とジェネリック医薬品を含む。ジェネリック医薬品はエリスロマイシンエチルコハク酸塩、メチルテストステロン(EEMT)を有するエステル化エストロゲン、エトドラクフェノフィブレート、フレカイニド、フルボキサミン、メタゾラミド、メトクロプラミドシロップニルタミド、ニモジピン、アヘンチンキ、オキシコドンカプセル、オキシコドン経口溶液、プロパフェノンおよびバンコマイシンなどを含む。ブランド製品にはコルテネーマ、インデラルLA、リトビッド、レグランおよびバンコシンが含まれる。同社の医薬品製造施設はミネソタ州ボーデットに位置する。   ANIファ―マシュ―ティカルズは米国の製薬会社。ブランドとジェネリックの医療用医薬品の開発、製造、販売に従事する。女性の性的健康、更年期障害、避妊と男性性腺機能低下症の治療用医薬品開発のほか、開発製品の対象は麻酔薬、抗がん薬、ホルモン・ステロイドおよび製剤を含む。本社はミネソタ州。   ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products.
本社所在地 210 Main Street West Baudette MN 56623 USA
代表者氏名 Robert E. Brown ロバートE.ブラウン
代表者役職名 Independent Chairman of the Board
電話番号 +1 218-634-3500
設立年月日 35278
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 173人
url www.anipharmaceuticals.com
nasdaq_url https://www.nasdaq.com/symbol/anip
adr_tso
EBITDA EBITDA(百万ドル) 62.04800
終値(lastsale) 54.83
時価総額(marketcap) 648570965.63
時価総額 時価総額(百万ドル) 656.49620
売上高 売上高(百万ドル) 189.20100
企業価値(EV) 企業価値(EV)(百万ドル) 806.10820
当期純利益 当期純利益(百万ドル) 13.49700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 ANI Pharmaceuticals Inc revenues increased 15% to $93.8M. Net income applicable to common stockholders increased 31% to $5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Stock-based Compensation in SGA decrease of 3% to $2.7M (expense).

 ANIPのテクニカル分析


 ANIPのニュース

   ANI Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  2021/02/19 21:30:00 Business Wire
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI“ or the “Company“) (Nasdaq: ANIP) today announced that ANI's Board of Directors granted non-qualified inducement stock options to purchase an aggregate of 27,006 shares of ANI's common stock to Ori Gutwerg, ANI’s Senior Vice President, Generics, and an aggregate of 33,758 shares to Christopher Mutz, ANI’s Chief Commercial Officer & Head of Rare Disease, effective February 15, 2021. The stock options were granted as inducement
   ANI Pharmaceuticals Announces Launch of Prazosin Hydrochloride (“HCl”) Capsules  2021/02/01 11:50:00 Business Wire
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Prazosin HCl Capsules USP, 1mg and 2mg, following the U.S. Food and Drug Administration’s (“FDA”) approval of the Company’s prior approval supplement application (“PAS”). The current annual U.S. market for Prazosin 1mg and 2mg strengths is approximately $46.2 million, according to IQVIA/IMS Health. "Launch of Prazosin HCl is ANI’s fourteenth re-commercialization of a
   Impact of COVID-19 on Vaginal Fungi Infections Treatment Market SWOT Analysis by 2027 | Pfizer Inc., Bausch Health Companies Inc, ANI Pharmaceuticals  2021/01/05 11:00:51 OpenPR
The latest 100+ page survey report on Vaginal Fungi Infections Treatment Market is released by CMI covering various players of the industry selected from global geographies like North America (Covered in Chapter 6 and 13), United States, Canada, Mexico, Europe
   Alagille Syndrome Market 2020-2026 Moving Towards Brighter Future | Major Giants – Endo Pharmaceuticals Inc, ANI Pharmaceuticals, Inc, Mylan N.V., Glenmark Pharmaceuticals Ltd, Amneal Pharmaceuticals LLC  2020/12/10 15:50:02 OpenPR
In Alagille Syndrome Market report, a systematic investment analysis has been performed which forecasts impending opportunities for the market players. The statistical and numerical data that has been included in this market report is represented with the tables, graphs and
   ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $46.00 Consensus PT from Brokerages  2020/10/24 14:56:45 Transcript Daily
Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been assigned an average rating of “Hold” from the seven brokerages that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month price […]
   ANI Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  2021/02/19 21:30:00 Business Wire
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI“ or the “Company“) (Nasdaq: ANIP) today announced that ANI's Board of Directors granted non-qualified inducement stock options to purchase an aggregate of 27,006 shares of ANI's common stock to Ori Gutwerg, ANI’s Senior Vice President, Generics, and an aggregate of 33,758 shares to Christopher Mutz, ANI’s Chief Commercial Officer & Head of Rare Disease, effective February 15, 2021. The stock options were granted as inducement
   ANI Pharmaceuticals Announces Launch of Prazosin Hydrochloride (“HCl”) Capsules  2021/02/01 11:50:00 Business Wire
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Prazosin HCl Capsules USP, 1mg and 2mg, following the U.S. Food and Drug Administration’s (“FDA”) approval of the Company’s prior approval supplement application (“PAS”). The current annual U.S. market for Prazosin 1mg and 2mg strengths is approximately $46.2 million, according to IQVIA/IMS Health. "Launch of Prazosin HCl is ANI’s fourteenth re-commercialization of a
   Impact of COVID-19 on Vaginal Fungi Infections Treatment Market SWOT Analysis by 2027 | Pfizer Inc., Bausch Health Companies Inc, ANI Pharmaceuticals  2021/01/05 11:00:51 OpenPR
The latest 100+ page survey report on Vaginal Fungi Infections Treatment Market is released by CMI covering various players of the industry selected from global geographies like North America (Covered in Chapter 6 and 13), United States, Canada, Mexico, Europe
   Alagille Syndrome Market 2020-2026 Moving Towards Brighter Future | Major Giants – Endo Pharmaceuticals Inc, ANI Pharmaceuticals, Inc, Mylan N.V., Glenmark Pharmaceuticals Ltd, Amneal Pharmaceuticals LLC  2020/12/10 15:50:02 OpenPR
In Alagille Syndrome Market report, a systematic investment analysis has been performed which forecasts impending opportunities for the market players. The statistical and numerical data that has been included in this market report is represented with the tables, graphs and
   ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $46.00 Consensus PT from Brokerages  2020/10/24 14:56:45 Transcript Daily
Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been assigned an average rating of “Hold” from the seven brokerages that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month price […]
   ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $46.00 Consensus PT from Brokerages  2020/10/24 14:56:45 Transcript Daily
Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been assigned an average rating of “Hold” from the seven brokerages that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month price […]
   ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $46.00 Consensus Target Price from Brokerages  2020/10/24 14:56:45 Transcript Daily
Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have received a consensus recommendation of “Hold” from the seven research firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and two have given a buy recommendation to the company. The […]
   ANI Pharmaceuticals (NASDAQ:ANIP) Downgraded to Strong Sell at ValuEngine  2020/10/24 03:22:46 Stock Observer
ValuEngine cut shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a sell rating to a strong sell rating in a report released on Wednesday, ValuEngine reports. A number of other brokerages also recently issued reports on ANIP. Raymond James cut their price target on shares of ANI Pharmaceuticals from $49.00 to $40.00 and set an outperform rating […]
   ValuEngine Downgrades ANI Pharmaceuticals (NASDAQ:ANIP) to Strong Sell  2020/10/23 05:24:46 Transcript Daily
ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Wednesday, ValuEngine reports. Other analysts have also issued reports about the stock. Raymond James cut their target price on shares of ANI Pharmaceuticals from $49.00 to $40.00 and set an “outperform” rating […]
   ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by ValuEngine  2020/10/23 05:24:45 Zolmax News
ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued on Wednesday, ValuEngine reports. Several other research firms have also commented on ANIP. Zacks Investment Research raised shares of ANI Pharmaceuticals from a “strong sell” rating to a “hold” rating in […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ANIファ―マシュ―ティカルズ ANIP ANI Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)